Nantahala Capital Management, LLC
Position in JANX — Janux Therapeutics, Inc.
CIK 1472322
New Canaan, CT
Position in JANX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$11,257,804
New position
Shares Held
809,914
first reported quarter
Ownership
1.33%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Nantahala Capital Management, LLC holds $599,967,806 across 52 Biotechnology names. JANX ranks #21 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLNO |
Soleno Therapeutics Inc
|
1,744,124 | $58,393,271 | |
| 2 | SVRA |
Savara Inc
|
7,344,783 | $40,102,515 | |
| 3 | IMUX |
Immunic, Inc.
|
2,506,491 | $27,822,050 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
1,250,452 | $26,159,455 | |
| 5 | LBRX |
Lb Pharmaceuticals Inc
|
1,052,894 | $25,964,366 | |
| 6 | MLYS |
Mineralys Therapeutics, Inc.
|
895,481 | $24,258,580 | |
| 7 | ZVRA |
Zevra Therapeutics, Inc.
|
2,521,936 | $23,504,443 | |
| 8 | FULC |
Fulcrum Therapeutics, Inc.
|
3,050,040 | $23,393,806 |
All Filings in JANX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,257,804 | 809,914 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||